J. Waldstreicher

发表

Bumps and bridges on the road to responsible sharing of clinical trial data

Frank W. Rockhold, Jesse A. Berlin, Davina Ghersi, 2014, Clinical trials.

The Yale Open Data Access (YODA) Project--A Mechanism for Data Sharing.

Harlan M Krumholz, H. Krumholz, J. Waldstreicher, 2016, The New England journal of medicine.

Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group.

C. Roehrborn, M. Resnick, S. Kaplan, 1999, Urology.

Technology-Enabled Clinical Trials: Transforming Medical Evidence Generation.

Norman Stockbridge, J Marc Overhage, Sameer Bansilal, 2019, Circulation.

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.

C. Roehrborn, G. Andriole, P. Walsh, 1998, The New England journal of medicine.

Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study.

P. Schellhammer, C. Roehrborn, M. Resnick, 2000, The Journal of urology.

Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease: indirect evidence for partial gonadotroph desensitization.

W. Crowley, N. Santoro, J. Waldstreicher, 1988, The Journal of clinical endocrinology and metabolism.

Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia.

J. Waldstreicher, E. Olsen, W. Bergfeld, 2000, Journal of the American Academy of Dermatology.

Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes.

C. Roehrborn, P. Narayan, B. Saltzman, 2002, European urology.

Gender differences in the temporal organization of proclactin (PRL) secretion: evidence for a sleep-independent circadian rhythm of circulating PRL levels- a clinical research center study.

C. Czeisler, J. Duffy, E. Brown, 1996, The Journal of clinical endocrinology and metabolism.

Development of a health‐related quality of life questionnaire for women with androgenetic alopecia

J. Waldstreicher, W. Bergfeld, C. Girman, 2000, Clinical and experimental dermatology.

Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study.

E. Crawford, G. Andriole, J. Epstein, 1998, Urology.

The PCAST Report: Impact and Implications for the Pharmaceutical Industry

S. Morris, J. Orloff, J. Waldstreicher, 2013, Clinical pharmacology and therapeutics.

The genetic and clinical heterogeneity of gonadotropin-releasing hormone deficiency in the human.

L. Holmes, W. Crowley, J. Jameson, 1996, The Journal of clinical endocrinology and metabolism.

Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy?

Ximing J. Yang, P. Schellhammer, J. Epstein, 1999 .

Urinary Retention in Patients with BPH Treated with Finasteride or Placebo over 4 Years

Clair E. Cox, C. Roehrborn, B. Brown, 2000, European Urology.

Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia.

S. Kaplan, P. Narayan, B. Saltzman, 2001, Urology.

Defective regulation of glycoprotein free alpha-subunit in males with isolated gonadotropin-releasing hormone deficiency--a clinical research center study.

W. Crowley, J. Waldstreicher, F. Pralong, 1995, The Journal of clinical endocrinology and metabolism.

Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and long-term response to finasteride. The Pless Study Group.

S. Kaplan, J. Waldstreicher, S. Rosenberg, 2000, Urology.

Patient-perceived importance of negative effects of androgenetic alopecia in women.

J. Waldstreicher, W. Bergfeld, C. Girman, 1999, Journal of women's health & gender-based medicine.

Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia.

M. Lieber, M. Elhilali, G. Andriole, 2003, Urology.

Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia.

J. Waldstreicher, A. Matsumoto, J. Rajfer, 2003, Urology.

The Long-Term Effect Of Specific Type II 5α-Reductase Inhibition With Finasteride on Bone Mineral Density in Men: Results of a 4-Year Placebo Controlled Trial

D. Kadmon, J. Waldstreicher, M. McClung, 2002 .

Designing, Conducting, Monitoring, and Analyzing Data from Pragmatic Randomized Clinical Trials: Proceedings from a Multi-stakeholder Think Tank Meeting

Lin Wang, Adrian F Hernandez, Jesse A Berlin, 2020, Therapeutic Innovation & Regulatory Science.

Prostate Volume and Serum Prostate–Specific Antigen as Predictors of Acute Urinary Retention

M. Marberger, J. Waldstreicher, J. Andersen, 2000, European Urology.

Globalized Pediatric Research

J. Berlin, J. Waldstreicher, J. Siegel, 2011, Pediatrics.

Drugs of unproven benefit for COVID-19: a pharma perspective on ethical allocation of available therapies.

A. Caplan, J. Waldstreicher, Karla Childers, 2020, The Journal of clinical investigation.

Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia.

C. Roehrborn, J. Gottesman, B. Saltzman, 2004, The Journal of urology.

Effects of finasteride on serum testosterone and body mass index in men with benign prostatic hyperplasia.

C. Roehrborn, J. Waldstreicher, A. Meehan, 2010, Urology.

Long-term (7 to 8-year) experience with finasteride in men with benign prostatic hyperplasia.

J. Imperato-McGinley, J. Waldstreicher, A. Matsumoto, 2002, Urology.

Androgen antagonists: Potential role in prostate cancer prevention.

D. Trump, J. Waldstreicher, B. Neubauer, 2001, Urology.

The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia.

J. Waldstreicher, D. Thiboutot, L. Drake, 1999, Journal of the American Academy of Dermatology.

The long-term effect of specific type II 5alpha-reductase inhibition with finasteride on bone mineral density in men: results of a 4-year placebo controlled trial.

D. Kadmon, J. Waldstreicher, M. McClung, 2002, The Journal of urology.

Intravenous administration of pulsatile gonadotropin-releasing hormone in hypothalamic amenorrhea: effects of dosage.

W. Crowley, N. Santoro, J. Waldstreicher, 1986, The Journal of clinical endocrinology and metabolism.

Effects of statins on biomarkers of bone metabolism: a randomised trial.

E. Stein, J. Waldstreicher, M. Farnier, 2001, NMCD. Nutrition Metabolism and Cardiovascular Diseases.

Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study.

P. Schellhammer, J. Epstein, J. Gottesman, 1999, Urology.

Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study.

P. Schellhammer, C. Roehrborn, M. Resnick, 2000, The Journal of urology.

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia

C. Roehrborn, G. Andriole, P. Walsh, 1998 .

Measuring reversal of hair miniaturization in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies: results of finasteride 1 mg treatment of men and postmenopausal women.

J. Waldstreicher, K. Kaufman, D. Whiting, 1999, The journal of investigative dermatology. Symposium proceedings.

Finasteride in the treatment of men with frontal male pattern hair loss.

M. Lebwohl, J. Leyden, J. Waldstreicher, 1999, Journal of the American Academy of Dermatology.

Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: effects of finasteride. The Finasteride PSA Study Group.

J. Oesterling, J. Waldstreicher, T. Krarup, 1997, Urology.

Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: effects of finasteride. Finasteride PSA Study Group.

J. Oesterling, J. Waldstreicher, T. Krarup, 1997, Urology.

A systemic type I 5 α-reductase inhibitor is ineffective in the treatment of acne vulgaris

A. Gottlieb, J. Strauss, Sewon Kang, 2004 .

Evaluating health-related quality of life in patients with facial acne: development of a self-administered questionnaire for clinical trials

J. Waldstreicher, D. Thiboutot, S. Hartmaier, 1996, Quality of Life Research.

Overview and experience of the YODA Project with clinical trial data sharing after 5 years

Harlan M Krumholz, Jesse A Berlin, Joseph S Ross, 2018, Scientific Data.

Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia.

P. Boyle, C. Roehrborn, A. Gould, 1999, Urology.

Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group.

P. Boyle, C. Roehrborn, R. deVere White, 1999, Urology.

A multirater validation study to assess the reliability of acne lesion counting.

J. Waldstreicher, C. Girman, A. Lucky, 1996, Journal of the American Academy of Dermatology.

Lowering low density lipoprotein cholesterol with simvastatin, a hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, does not affect luteal function in premenopausal women.

S. Nakajima, N. Santoro, J. Waldstreicher, 2002, The Journal of clinical endocrinology and metabolism.

Individual Patient-Level Data Sharing for Continuous Learning: A Strategy for Trial Data Sharing.

Harlan M. Krumholz, Eric D. Peterson, Alexander Ommaya, 2019, NAM perspectives.

A Pilot Experiment in Responding to Individual Patient Requests for Compassionate Use of an Unapproved Drug: The Compassionate Use Advisory Committee (CompAC)

A. Caplan, J. Waldstreicher, Alison Bateman-House, 2019, Therapeutic innovation & regulatory science.

Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. PLESS Study Group. Proscar Long-term Efficacy and Safety Study.

J. Waldstreicher, C. Girman, J. Fowler, 1999, Urology.

Data Acquisition, Curation, and Use for a Continuously Learning Health System.

Harlan M. Krumholz, Sharon F. Terry, H. Krumholz, 2016, JAMA.

Managing Conflicts of Interest in Industry-Sponsored Clinical Research: More Physician Engagement Is Required

J. Waldstreicher, Michael E. Johns, 2017, JAMA.

Data Acquisition, Curation, and Use For a Continuously Learning Health System: A Vital Direction for Health and Health Care

Medtronic, H. Krumholz, S. Terry, 2016 .

A systemic type I 5 alpha-reductase inhibitor is ineffective in the treatment of acne vulgaris.

A. Gottlieb, J. Strauss, Sewon Kang, 2004, Journal of American Academy of Dermatology.

ANOREXIA NERVOSA PRESENTING AS MORBID EXERCISING

J. Waldstreicher, 1985, The Lancet.

Lessons From COVID-19 for Pandemic Preparedness: Proceedings From a Multistakeholder Think Tank

N. Stockbridge, Adrian F. Hernandez, M. A. Moody, 2023, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.